In vitro and in vivo silencing of the androgen receptor

Methods Mol Biol. 2011:776:95-112. doi: 10.1007/978-1-61779-243-4_7.

Abstract

The androgen receptor (AR) plays a pivotal role in the progression of prostate cancer from the androgen-dependent to the castration-resistant state, making it a potential target for therapy. In this chapter, we describe the preparation and use of sublines of LNCaP and C4-2 human prostate cancer cells which have been engineered to stably express a doxycycline (DOX)-inducible AR shRNA in order to study the in vitro and in vivo effects of AR knockdown.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Base Sequence
  • Biological Assay
  • Cell Line, Tumor
  • Cell Proliferation
  • Cloning, Molecular
  • Doxycycline / pharmacology
  • Gene Expression Regulation / drug effects
  • Gene Knockdown Techniques
  • Gene Silencing*
  • Gene Transfer Techniques
  • Genetic Vectors / genetics
  • HEK293 Cells
  • Humans
  • Male
  • Mice
  • Mice, Nude
  • RNA, Small Interfering / genetics
  • RNA, Small Interfering / metabolism
  • Receptors, Androgen / genetics*
  • Receptors, Androgen / metabolism*
  • Recombination, Genetic
  • Repressor Proteins / drug effects
  • Repressor Proteins / genetics
  • Transcription, Genetic
  • Xenograft Model Antitumor Assays

Substances

  • RNA, Small Interfering
  • Receptors, Androgen
  • Repressor Proteins
  • tetracycline resistance-encoding transposon repressor protein
  • Doxycycline